Gland Pharma Ltd

BSE: 543245 NSE: GLAND
Gland Pharma Ltd - healthcare in Hyderabad, Telangana, India. FY 2026 financials & compliance.
CIN L24239TG1978PLC002276 Incorporated 20 March 1978 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Listed - NSE: GLAND · BSE: 543245 Public Limited Company healthcare Fortune India 500 · #414 Fortune MNC 500 · #135 Nifty 500
Data last updated
Market Cap
₹46,927 Cr
GLAND · NSE
Share Price
₹2,960.30
+4.09% today
Revenue
₹6,431 Cr
FY 2025-26 · +14.5% YoY
EBITDA
₹1,605 Cr
Margin 25.0%
Net Profit
₹1,042 Cr
FY 2025-26 · +49.5% YoY
P/E (TTM)
40.7x
P/B 4.5x
ROE
10.5%
ROCE 14.6%
Debt / Equity
0.03
Interest cover 2.8x

About Gland Pharma Ltd

Data last updated:

Gland Pharma Ltd is a public limited company based in Hyderabad, Telangana, India, a subsidiary of Fosun Pharma Industrial Pte Ltd. It operates in the medical and laboratory equipment segment of the healthcare sector. It was incorporated on 20 March 1978 and has been in existence for over 48 years.

Gland Pharma is ranked #414 on the Fortune India 500 (2025) and #135 on the Fortune MNC 500 India (2026). It is part of the Nifty 500 and BSE 500 indices.

The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN L24239TG1978PLC002276. Its GSTIN is 03AAACG8036B1Z8 (Punjab). The company holds 9 GST registrations, of which 8 are active. It is a listed company as per MCA records. Its shares are listed on BSE: 543245 and NSE: GLAND.

The company has an authorised share capital of ₹56.3 Cr and a paid-up capital of ₹16.5 Cr. It was formerly known as Gland Pharma Pvt Ltd. It is led by directors including Srinivas Sadu (Whole-Time Director) and Jia Ai Zhang.

Its last annual general meeting (AGM) was held on 25 August 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Hyderabad, Telangana.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹6,430.65 Cr, a growth of 14.5% compared to the previous year. For the same year it recorded a net profit of ₹1,042.05 Cr (net margin 16.2%) and EBITDA of ₹1,605.2 Cr (EBITDA margin 25%). The net worth stands at ₹10,358 Cr (up 13.2% YoY). Total assets are valued at ₹10,878 Cr (up 12.7% YoY).

The company has about 4,769 employees on its provident fund (EPFO) records.

The company is associated with 1 brand: Gland Pharma. As per MCA filings, the company has satisfied charges of ₹566.83 Cr on record. Court records list 82 cases involving the company, including 53 filed by the company and 29 filed against it; 14 cases are pending. The company has 32 deals on record (14 secondary share transfers, 11 market trades, 6 funding rounds), with disclosed funding of ₹1,235.71 Cr; the latest was in September 2026. Its 7 peer companies in the Healthcare industry (API Manufacturers, Medical and Laboratory Equipment), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 3 larger and 4 smaller; the largest is Apitoria Pharma Private Limited with revenue of ₹6,811.62 Cr.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website glandpharma.com.

Company details

CIN L24239TG1978PLC002276
Registration Number 002276
Incorporation Date 20 March 1978
ROC Hyderabad
Listing Status Listed - Listed on NSE (GLAND); Listed on BSE (543245)
Company Status Active
Date of Last AGM 25 August 2026
Date of Balance Sheet 31 March 2026
Parent Company Fosun Pharma Industrial Pte Ltd
Compliance Status Active Compliant

CIN history

Gland Pharma has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L24239TG1978PLC002276, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L24239TG1978PLC002276Current
U24239AP1978PLC002276Previous
U24239TG1978PLC002276Previous
Key People
Srinivas Sadu Whole-Time Director Jia Ai Zhang Director Naina Lal Kidwai Director

Recognitions & Rankings of Gland Pharma

Fortune India 500 2025 edition
Rank#414
Total income
₹5,727 Cr
Profit
₹699 Cr
Last year #382
Fortune MNC 500 India 2026 edition
Rank#135
Total income
₹5,727 Cr
Profit
₹699 Cr
Last year #124
Stock market indices
Nifty 500 BSE 500

Contact details

Gland Pharma Ltd's registered office is in Medchal Malkajgiri District Hyderabad, Telangana. Its website is glandpharma.com. Its e-mail address and telephone number are in the company report.

  • Email
  • Telephone
  • Website
    glandpharma.com
  • Social Media
  • Registered Address
    Sy.No.143 – 148 150 &151 Near Gandi Maisamma X Roads D.P.Pally Dundigal – Gandimais, Amma(M), Hyderabad, Telangana, India – 500043
  • Industry
    Healthcare, Medical & Laboratory Equipment

To see the full contact details of Gland Pharma Ltd, buy the company report.

Comprehensive company report
Gland Pharma Ltd - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Brands

Gland Pharma operates one associated brand: Gland Pharma. Each brand links to its own profile.

BrandDescriptionWebsite
Gland Pharma
Generic injectable drugs are manufactured across therapeutic segments.glandpharma.com

Business activity

The main business activity of Gland Pharma is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main activity group codeMain activityBusiness activity codeBusiness activityShare of turnover
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products

To see the full business activity and turnover split of Gland Pharma Ltd, buy the company report.

Financials of Gland Pharma Ltd

FY 2025-26 filings available

Gland Pharma Ltd reported revenue of ₹6,430.65 Cr (up 14.5% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹6,431 Cr
+14.5% YoY
EBITDA
₹1,605 Cr
+26.5% YoY
Profit After Tax
₹1,042 Cr
+49.5% YoY
Net Worth
₹10,358 Cr
+13.2% YoY
Total Assets
₹10,878 Cr
+12.7% YoY
Total Debt
₹284 Cr
-9.6% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue6,4315,6165,6653,6254,4013,4632,633
Revenue growth+14.5%-0.9%+56.3%-17.6%+27.1%+31.5%-
EBITDA1,6051,2691,3339681,5101,302955
EBITDA margin+25.0%+22.6%+23.5%+26.7%+34.3%+37.6%+36.3%
Profit before tax1,4651,0631,1331,0551,6191,335993
Net profit1,0426977728211,208997760
Net profit margin+16.2%+12.4%+13.6%+22.6%+27.5%+28.8%+28.9%
EPS (₹)62.3542.4046.9047.4273.7560.9449.88
Balance sheet
Total assets10,8789,6529,2747,9657,1645,9103,654
Net worth10,3589,1518,7247,9597,1585,9033,646
Total debt2843143724.454.745.004.96
Cash & bank3,3592,5561,8393,7713,0933,0061,325
Net working capital6,1095,4254,4786,1725,1154,6112,488
Cash flow
Cash from operations1,031915997364791605701
Cash from investing1881,718(1,749)1,211(999)(1,520)(761)
Cash from financing(417)(433)(799)14.9234.901,238(6.87)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,8001,7431,6951,4871,5061,4251,3841,406
Revenue growth (YoY)+19.6%+22.3%+22.5%+5.8%+7.4%---
Other income61.2311163.1784.1657.5344.0358.4959.66
EBITDA489513411314368348360297
EBITDA margin+27.2%+29.4%+24.2%+21.1%+24.4%+24.4%+26.0%+21.1%
Depreciation11110910810610195.7696.3393.83
Interest4.3610.033.937.8211.507.4522.826.11
Profit before tax435506362284313288299257
Tax11813910110097.2610294.6193.24
Net profit317367261184215187205164
EPS (₹)19.2222.2315.8711.1513.0811.3212.429.93
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue4,5524,1164,1673,6174,4013,4632,633
Revenue growth+10.6%-1.2%+15.2%-17.8%+27.1%+31.5%-
EBITDA1,6391,4431,4099621,5111,302955
EBITDA margin+36.0%+35.1%+33.8%+26.6%+34.3%+37.6%+36.3%
Profit before tax1,7481,4661,4051,0481,6191,335993
Net profit1,3151,0881,0448151,209997760
Net profit margin+28.9%+26.4%+25.0%+22.6%+27.5%+28.8%+28.9%
EPS (₹)78.8866.1463.3447.1173.7860.9549.88
Balance sheet
Total assets10,8609,7839,0207,9597,1655,9103,654
Net worth10,8109,7558,9957,9537,1585,9033,646
Total debt2.755.233.664.454.745.004.96
Cash & bank3,1782,4331,5993,7673,0863,0051,325
Net working capital5,7895,2454,1586,1595,1084,6112,488
Cash flow
Cash from operations1,1351,0741,136368791605701
Cash from investing(74.03)1,582(2,918)1,211(1,007)(1,521)(761)
Cash from financing(316)(340)(7.40)14.9234.901,238(6.87)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,2871,2621,1781,0741,0391,0301,0111,063
Revenue growth (YoY)+23.9%+22.4%+16.5%+1.1%+2.7%---
Other income58.8210660.2182.5954.7443.7265.0657.80
Total expenses813754780699680636620699
EBITDA474508397375359394391364
EBITDA margin+36.8%+40.2%+33.7%+34.9%+34.5%+38.3%+38.7%+34.2%
Depreciation43.9543.1144.5344.8443.7743.0743.7741.62
Interest0.696.170.503.977.443.4518.310.17
Profit before tax488565412409362391394380
Tax12314410510793.1210199.0198.10

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 27 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,8001,7431,6951,4871,5061,4251,3841,406
Revenue growth (YoY)+19.6%+22.3%+22.5%+5.8%+7.4%---
Other income61.2311163.1784.1657.5344.0358.4959.66
EBITDA489513411314368348360297
EBITDA margin+27.2%+29.4%+24.2%+21.1%+24.4%+24.4%+26.0%+21.1%
Depreciation11110910810610195.7696.3393.83
Interest4.3610.033.937.8211.507.4522.826.11
Profit before tax435506362284313288299257
Tax11813910110097.2610294.6193.24
Net profit317367261184215187205164
EPS (₹)19.2222.2315.8711.1513.0811.3212.429.93
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue6,4315,6165,6653,6254,4013,4632,633
Revenue growth+14.5%-0.9%+56.3%-17.6%+27.1%+31.5%-
Other income316214170240224135139
Total expenses4,8254,3484,3322,6562,8912,1611,678
Employee cost1,6291,4021,257403339311278
EBITDA1,6051,2691,3339681,5101,302955
EBITDA margin+25.0%+22.6%+23.5%+26.7%+34.3%+37.6%+36.3%
Depreciation42437834514711098.7894.59
Interest33.2842.0026.207.455.243.417.18
Profit before tax1,4651,0631,1331,0551,6191,335993
Tax437364360274407338220
Net profit1,0426977728211,208997760
Net profit margin+16.2%+12.4%+13.6%+22.6%+27.5%+28.8%+28.9%
EPS (₹)62.3542.4046.9047.4273.7560.9449.88
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital16.4816.4816.4716.4716.4316.3615.50
Reserves & surplus10,3419,1348,7077,9427,1415,8873,631
Shareholders' funds (net worth)10,3589,1518,7247,9597,1585,9033,646
Minority interest0.000.000.000.000.000.000.00
Secured loans0.000.000.000.000.000.000.00
Unsecured loans2843143724.454.745.004.96
Total debt2843143724.454.745.004.96
Total liabilities10,8789,6529,2747,9657,1645,9103,654
Assets
Gross block6,7855,6135,0122,2952,0811,4311,348
Net block4,4924,1473,9471,5711,502954968
Capital work in progress342151238177191338188
Investments0.000.000.000.001550.000.00
Inventories1,7441,6851,6551,9451,1861,275756
Sundry debtors1,8911,5171,5598711,199671602
Cash & bank balances3,3592,5561,8393,7713,0933,0061,325
Loans & advances5321,025592313219172163
Total current assets7,5276,7835,6456,9015,6975,1242,846
Total current liabilities1,4181,3581,167728582512358
Net working capital6,1095,4254,4786,1725,1154,6112,488
Total assets10,8789,6529,2747,9657,1645,9103,654
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash2,5563571,909319492170236
Net cash from operating activities1,031915997364791605701
Net cash from investing activities1881,718(1,749)1,211(999)(1,520)(761)
Net cash from financing activities(417)(433)(799)14.9234.901,238(6.87)
Net change in cash8032,199(1,552)1,590(174)323(66.91)
Closing cash3,3592,5561,8393,7713,0933,0061,325
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+14.5%-0.9%+56.3%-17.6%+27.1%+31.5%-
EBITDA growth+26.5%-4.8%+37.7%-35.9%+16.0%+36.3%-
PBT growth+37.8%-6.2%+7.4%-34.8%+21.3%+34.4%+9997.0%
Net income growth+49.5%-9.7%-5.9%-32.1%+21.2%+31.2%-
Revenue CAGR (3Y)+21.1%+8.5%+17.8%+11.2%---
EBITDA CAGR (3Y)+18.4%-5.6%+0.8%+0.5%---
Profitability & leverage
Net income margin+16.0%+12.4%+13.6%+21.6%+27.5%+28.8%+29.4%
Return on capital employed+14.6%+11.7%+13.4%+14.0%+24.8%+28.0%+27.4%
Return on net worth+10.5%+7.8%+9.3%+10.3%+18.6%+20.9%+21.2%
Debt / equity0.030.040.020.000.000.000.00
Long-term debt / equity0.010.010.010.000.000.000.00
Interest cover2.824.712.650.910.370.280.83
Efficiency & per share
Fixed asset turnover1.041.061.551.662.512.491.95
Inventory turnover3.753.363.152.323.583.413.48
Debtors turnover3.773.654.663.724.715.444.38
EPS (₹)62.3542.4046.9047.4273.7560.9449.88
Dividend per share (₹)20.0018.0020.000.000.000.000.00
Book value per share (₹)628.67555.40529.65483.23435.64360.86235.32
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue1,2871,2621,1781,0741,0391,0301,0111,063
Revenue growth (YoY)+23.9%+22.4%+16.5%+1.1%+2.7%---
Other income58.8210660.2182.5954.7443.7265.0657.80
Total expenses813754780699680636620699
EBITDA474508397375359394391364
EBITDA margin+36.8%+40.2%+33.7%+34.9%+34.5%+38.3%+38.7%+34.2%
Depreciation43.9543.1144.5344.8443.7743.0743.7741.62
Interest0.696.170.503.977.443.4518.310.17
Profit before tax488565412409362391394380
Tax12314410510793.1210199.0198.10
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue4,5524,1164,1673,6174,4013,4632,633
Revenue growth+10.6%-1.2%+15.2%-17.8%+27.1%+31.5%-
Other income304215167240224135139
Total expenses2,9132,6742,7592,6542,8902,1611,678
Employee cost529439410400339311278
EBITDA1,6391,4431,4099621,5111,302955
EBITDA margin+36.0%+35.1%+33.8%+26.6%+34.3%+37.6%+36.3%
Depreciation17616916214711098.7894.59
Interest18.0722.847.847.415.243.417.18
Profit before tax1,7481,4661,4051,0481,6191,335993
Tax449376362273407338220
Net profit1,3151,0881,0448151,209997760
Net profit margin+28.9%+26.4%+25.0%+22.6%+27.5%+28.8%+28.9%
EPS (₹)78.8866.1463.3447.1173.7860.9549.88
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital16.4816.4816.4716.4716.4316.3615.50
Reserves & surplus10,7949,7398,9797,9377,1425,8873,631
Shareholders' funds (net worth)10,8109,7558,9957,9537,1585,9033,646
Secured loans0.000.000.000.000.000.000.00
Unsecured loans2.755.233.664.454.745.004.96
Total debt2.755.233.664.454.745.004.96
Total liabilities10,8609,7839,0207,9597,1655,9103,654
Assets
Gross block2,9152,7982,5802,2952,0811,4311,348
Net block1,6881,7451,6941,5711,502954968
Capital work in progress13842.21120177191338188
Investments3,2932,7902,3868.161630.550.00
Inventories1,2651,2541,2601,9451,1861,275756
Sundry debtors1,5211,1431,1718631,075671602
Cash & bank balances3,1782,4331,5993,7673,0863,0051,325
Loans & advances459937541313343172163
Total current assets6,4225,7674,5716,8885,6905,1232,846
Total current liabilities633522413729582512358
Net working capital5,7895,2454,1586,1595,1084,6112,488
Total assets10,8609,7839,0207,9597,1655,9103,654
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash2,4331161,905311492170236
Net cash from operating activities1,1351,0741,136368791605701
Net cash from investing activities(74.03)1,582(2,918)1,211(1,007)(1,521)(761)
Net cash from financing activities(316)(340)(7.40)14.9234.901,238(6.87)
Net change in cash7452,316(1,789)1,594(181)322(66.91)
Closing cash3,1782,4331,5993,7673,0863,0051,325
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+10.6%-1.2%+15.2%-17.8%+27.1%+31.5%-
EBITDA growth+13.6%+2.4%+46.4%-36.3%+16.0%+36.3%-
PBT growth+19.3%+4.3%+34.1%-35.3%+21.3%+34.5%+44.7%
Net income growth+20.9%+4.3%+28.0%-32.6%+21.3%+31.2%-
Revenue CAGR (3Y)+8.0%-2.2%+6.4%+11.2%+29.1%+28.8%+21.2%
EBITDA CAGR (3Y)+19.4%-1.5%+2.7%+0.2%+30.1%+34.5%+15.2%
Profitability & leverage
Net income margin+28.6%+26.5%+25.0%+21.5%+27.5%+28.8%+29.4%
Return on capital employed+17.1%+15.8%+16.7%+14.0%+24.9%+28.0%+30.6%
Return on net worth+12.6%+11.6%+12.3%+10.3%+18.6%+20.9%+23.8%
Debt / equity0.000.000.000.000.000.000.00
Long-term debt / equity0.000.000.000.000.000.000.00
Interest cover1.241.790.630.910.370.280.83
Efficiency & per share
Fixed asset turnover1.591.531.711.652.512.492.05
Inventory turnover3.613.272.602.313.583.413.16
Debtors turnover3.423.564.103.735.045.444.75
EPS (₹)78.8866.1463.3447.1173.7860.9549.88
Dividend per share (₹)20.0018.0020.000.000.000.000.00
Book value per share (₹)656.11592.08546.13482.90435.68360.86235.32

To see the full year-wise statements and ratios of Gland Pharma Ltd, buy the company report.

Board of directors of Gland Pharma Ltd

Gland Pharma has 8 current directors and 27 former directors. Current directors are listed first, with their designation and appointment date.

Current Directors
NameDesignationAppointment DateTenureStatus
Jia Ai ZhangDirector17 May 20215 Years 5 MonthsCurrent
Naina Lal Kidwai
Also directs: Upl Limited, Biocon Limited, Nayara Energy Limited and 1 more
Director17 May 20215 Years 5 MonthsCurrent
Essaji Goolam Vahanvati
Also directs: Agb Oils LLP, Bagh Tola Jungle Lodges LLP, R & V Legal Advisors LLP and 5 more
Director30 Sep 20206 Years 0 MonthsCurrent
Srinivas Sadu
Also directs: Sadu Advisory Services Private Limited
Whole-Time Director25 Apr 20197 Years 6 MonthsCurrent
Udo Jahannes Vetter
Also directs: Paschal Form Work (India) Private Limited
Director07 Feb 20188 Years 8 MonthsCurrent
Wei HuangDirector04 Nov 20241 Years 11 MonthsCurrent
Showing 6 of 8 current directors. View all directors

Peer comparison

Gland Pharma Ltd is compared with the 7 companies closest to it by revenue in the Healthcare industry (API Manufacturers, Medical and Laboratory Equipment), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Apitoria Pharma Private Limited₹6,811.62 Cr (FY 2025)20.0%Hyderabad, Telangana, India
MSN Laboratories Private Limited₹6,761.18 Cr (FY 2024)27.0%Hyderabad, Telangana, India
Alembic Pharmaceuticals Limited₹6,714.63 Cr (FY 2025)7.0%Vadodara, Gujarat, India
Gland Pharma Ltdthis company₹6,430.65 Cr (FY 2026)₹1,042.05 Cr16.2%14.5%4,769Hyderabad, Telangana, India
Laurus Labs Limited₹5,613.89 Cr (FY 2025)11.0%Anakapalle, Andhra Pradesh, India
Usv Private Limited₹5,202.13 Cr (FY 2025)7.0%Mumbai, Maharashtra, India
Natco Pharma Limited₹4,784 Cr (FY 2025)16.0%Hyderabad, Telangana, India
Granules India Limited₹4,494.53 Cr (FY 2025)0.0%Hyderabad, Telangana, India

To see the full peer comparison of Gland Pharma Ltd, buy the company report.

Auditor

Gland Pharma Ltd is audited by S.R. Batliboi & Associates LLP for the financial year 2022.

Auditor firmFinancial yearFirm registration number
S.R. Batliboi & Associates LLPFY 2022101049W/E300004

Shareholding

Shareholding for the quarter ended Sep 2026: promoters hold 51.80%, foreign institutional investors hold 8.70%, domestic institutional investors hold 30.50% and retail and other public shareholders hold 9.10%.

Promoters: 51.80%DII (Domestic Institutional): 30.50%FII (Foreign Institutional): 8.70%Retail & Others: 9.10%
Sep 2026
QUARTER
51.80% Promoters
30.50% DII (Domestic Institutional)
8.70% FII (Foreign Institutional)
9.10% Retail & Others
Promoter holding - history
Now 51.80% · Sep 2026High 51.80% · Dec 2025Low 51.80% · Dec 2025
50%50.8%51.5%52.3%53%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 51.80%Mar 2026: 51.80%Jun 2026: 51.80%Sep 2026: 51.80%51.80%51.80%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters51.80%51.80%51.80%51.80%
Public48.20%48.20%48.20%48.20%

Charges & borrowings

Open charges
None
Satisfied charges
₹566.83 Cr
Breakdown by lending institutions
Syndicate Bank₹292.53 Cr
The Bank of Nova Scotia₹140.00 Cr
Icici Bank Limited₹100.00 Cr
Export Import Bank of India₹30.80 Cr
Technology Development Board₹3.50 Cr
Latest charge details
DateCharge IDLenderAmountStatusModified or satisfied on
10 Sep 201210378069Icici Bank Limited₹100 CrSatisfied
30 Jun 201210364728Syndicate Bank₹100 CrSatisfied
06 Sep 200580010582The Bank of Nova Scotia₹140 CrSatisfied
13 Dec 200480010628Syndicate Bank₹7.5 CrSatisfied
09 Sep 200480010590Export Import Bank of India₹10 CrSatisfied

To see the full charge records of Gland Pharma Ltd, buy the company report.

Total charge records: 11 View all charges

Deals & funding

Gland Pharma Ltd has 32 deals on record (14 secondary share transfers, 11 market trades, 6 funding rounds), with disclosed funding of ₹1,235.71 Cr; the latest was in September 2026.

Total deals
32
Secondary share transfers
14
Market trades
11
Funding rounds
6
IPO
1
Disclosed funding
₹1,235.71 Cr

Deals on record (5 of 32)

WhenDealAmountParties
Sep 2026Market trade₹2,121.51 CrBuyer: Kotak Mahindra Mutual Fund, Axis Mutual Fund, Icici Prudential Mutual Fund
Seller: Fosun Pharma Industrial Pte. Ltd.
Apr 2024Market trade₹1,411.57 CrSeller: Lakumi Trust, Nicomac Machinery Private Limited
Aug 2023Market trade₹188.75 CrBuyer: Graviton Research Capital LLP
Seller: Graviton Research Capital LLP
Apr 2022Market trade₹1,721.75 CrSeller: Nicomac Machinery Private Limited
Nov 2020IPO₹6,479.55 CrInvestors: GIC Singapore, Goldman sachs India, HDFC Life Insurance Company Limited
Seller: Empower Trust, Nilay Trust, 2 individuals

To see the full deal history of Gland Pharma Ltd, buy the company report.

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME payment delays

No delayed payments to MSME suppliers are on our record for Gland Pharma Ltd; the supplier-wise MSME Form 1 check is in the company report Buy the company report.

Employees & EPFO

Gland Pharma Ltd has a workforce of 4,769 employees on its EPFO records as of Mar 31, 2024, across 1 active EPFO establishment.

Employee count
4,769
Active EPFO establishments
1
Employee growth
1.86%

GST

Gland Pharma has 9 GST registrations: 8 active and 1 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
9
Active
8
Cancelled / inactive
1
GSTINStateStatusRegistered on
03AAACG8036B1Z8PunjabActive01 Jul 2017
07AAACG8036B1Z0DelhiActive01 Jul 2017
29AAACG8036B1ZUKarnatakaActive01 Jul 2017
32AAACG8036B1Z7KeralaActive01 Jul 2017

To see the full GST registrations and return filing status of Gland Pharma Ltd, buy the company report.

Recent activity

Gland Pharma Ltd has 59 board changes on record since 1979: 34 appointments and 25 cessations. The latest: Xingli Wang was appointed as Additional Director on 01 Oct 2026.

Appointed
Xingli Wang was appointed as Additional Director.
AGM
Gland Pharma Ltd last Annual general meeting of members was held on 25 Aug 2026 as per latest MCA records.
Appointed
William Robert Keller was appointed as Director.
Filing
Gland Pharma Ltd has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Hyderabad.
Appointed
Shyamakant Binda Giri was appointed as CEO.
Appointed
Wei Huang was appointed as Director.
Ceased
Qiyu Chen ceased to be Director.
Ceased
Yao Fang ceased to be Director.
Ceased
Yiu Kwan Stanley Lau ceased to be Director.
Ceased
Xiaohui Guan ceased to be Director.
Ceased
Yifang Wu ceased to be Director.
Ceased
Li Dongming ceased to be Director.

76 earlier events are in the company report.

News

GLAND: Rs. 28.31 Crores BSE Block Trade; for ~ 100,031 Shares, at Rs. 2830.35
26 Oct 2026 · Exchange Update
GLAND: Rs. 37.23 Crores BSE Block Trade; for ~ 122,556 Shares, at Rs. 3038.00
19 Oct 2026 · Exchange Update
GLAND: Rs. 18.16 Crores BSE Block Trade; for ~ 59,769 Shares, at Rs. 3038.00
19 Oct 2026 · Exchange Update
GLAND: RS. 71.91 CRORES BSE BLOCK TRADE; FOR ~ 235,000 SHARES, AT RS. 3060.00
14 Oct 2026 · Exchange Update
Gland Pharma: Nomura on Gland Pharma Buy, Target Price ₹3,750; CDMO, biologics and in-licensing pivot underpin ~20% guided revenue CAGR, with Cenexi stabilising and biologics/specialty as the next growth legs; at 30.6x one-year-forward P/E, valuation expansion is warranted if biologics CDMO capabilities and innovator-client traction strengthen the structural shift toward CDMO.
07 Oct 2026 · Exchange Update

Frequently asked questions

Gland Pharma is an active public limited company based in Hyderabad, Telangana, India. The company works in medical and laboratory equipment, within the healthcare industry. It was incorporated on 20 March 1978 (48+ years old) and is registered under CIN L24239TG1978PLC002276. Listed on BSE: 543245 and NSE: GLAND.

Gland Pharma reported revenue of ₹6,430.65 Cr for FY 2025-26 (up 14.5% YoY) based on consolidated financials.

Gland Pharma has 8 current directors:

The latest financial statements of Gland Pharma on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 25 August 2026. Year-wise statements from 2015 are in the company report.

The GSTIN of Gland Pharma is 03AAACG8036B1Z8, registered in Punjab. The company has 9 GST registrations in all, of which 8 are active and 1 is cancelled or inactive. Other active GSTINs include 07AAACG8036B1Z0 (Delhi), 29AAACG8036B1ZU (Karnataka), 32AAACG8036B1Z7 (Kerala).

The CIN (Corporate Identification Number) of Gland Pharma is L24239TG1978PLC002276. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Gland Pharma is a listed company as per MCA records. Its shares are listed on both BSE (code: 543245) and NSE (symbol: GLAND).

Gland Pharma has 82 court cases on record: 53 filed by the company and 29 filed against it. 14 are pending. Most are in the high courts.

Gland Pharma was incorporated on 20 March 1978, making it 48+ years old. It is registered with the Registrar of Companies, Hyderabad.

Gland Pharma has 32 deals on record (14 secondary share transfers, 11 market trades, 6 funding rounds), with disclosed funding of ₹1,235.71 Cr; the latest was in September 2026.

The peers of Gland Pharma by revenue are Apitoria Pharma Private Limited, MSN Laboratories Private Limited, Alembic Pharmaceuticals Limited, Laurus Labs Limited, Usv Private Limited and 2 more, all in the Healthcare industry (API Manufacturers, Medical and Laboratory Equipment), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).